Home

NFLIS-Drug

1.5 million drug reports in 2019

Established in 1997, the National Forensic Laboratory Information System (NFLIS) is a program of the Drug Enforcement Administration (DEA), Diversion Control Division. The DEA's NFLIS-Drug data collection systematically collects drug identification results and associated information from drug cases submitted to and analyzed by participating Federal, State, and local forensic laboratories with drug chemistry sections. The 2019 NFLIS-Drug Annual Report showed that a total of 1,521,360 drug reports were identified by State and local forensic laboratories in the United States.
Learn More
NFLIS-TOX

About 39 million toxicology requests were referred to responding toxicology laboratories in 2016

Toxicology laboratories are a vital source for identifying drugs used by the public. Data from toxicology laboratories can serve as an early warning system to alert the public health community and law enforcement of the drugs they may encounter, leading to improved treatment, prevention, and enforcement policies. The addition of toxicology data to NFLIS is vital for helping DEA improve drug scheduling, enhance available drug intelligence, and better engage their public health partners.
Learn More
NFLIS-MEC

About 500,000 human death cases were accepted by Medical/Coroner offices in 2016

Medical Examiner and coroner offices (MECs) are an important data resource for identifying drugs that are used by the public and are potentially deadly. The addition of NFLIS-MEC will help DEA improve drug scheduling, enhance available drug intelligence, and better engage their public safety and public health partners.
Learn More

Overview Publications FAQs

Join NFLIS

Laboratory workers looking at NFLIS website on a laptop

Forensic Laboratories

Toxicology Laboratories

Medical Examiners and Coroners Offices

DEA Diversion Website Synth-Opioid Network Contact Us

NFLIS News

NFLIS DEA Synth-Opioids 2020 Annual Report

The NFLIS DEA Synth-Opioids forum has transitioned from an e-mail based communication network to a permanent, secure communication platform. During 2020, members assisted each other in attempting to identify nine unknown substances and discussed more than a dozen other substances or classes of compounds across the United States and in other countries.

Get the report.
Announcement of an Emerging Synthetic Opioid: 2-Naphthyl U-47700

A recent post on NFLIS DEA Synth-Opioids reported the first occurrence of 2-naphthyl U-47700 in case samples from Ohio. The samples also contained tramadol, fentanyl, and heroin.

Get the announcement.
Announcement of an Emerging Fentanyl-Related Compound: ortho-Chlorofentanyl

NFLIS DEA Synth-Opioids participants from Florida and Ohio have identified the emerging substance ortho-chlorofentanyl in recent case samples.

Get the announcement.
NFLIS-Drug Snapshot (March 2021)

Six new drugs were reported to NFLIS-Drug for the first time between January 1 and March 31, 2021. Get the snapshot.
Announcement of an Emerging Synthetic Cathinone 3,4-Methylenedioxy-PV8

A recent post on NFLIS DEA Synth-Opioids reported the first occurrence of 3,4-Methylenedioxy-PV8 in Alabama. The sample also contained cocaine and caffeine. Get the announcement.
NFLIS-Drug 2020 Midyear Report

Methamphetamine was the most frequently identified drug, followed by cannabis/THC, cocaine, fentanyl, and heroin. These five most frequently identified drugs accounted for approximately 75% of all drug reports. Get the report.
2019 Annual Report

Reports of fentanyl and buprenorphine increased significantly from 2018 to 2019. Get the report.
NFLIS MEC/Tox Brief: Toxicology Testing Practices for Benzodiazepines in the United States

1/7/2021: ** The Drug Enforcement Administration would like to announce the availability of the NFLIS MEC/Tox Brief: Toxicology Testing Practices for Benzodiazepines in the United States.